| Literature DB >> 35458129 |
Cristina Schiopu1,2, Gabriela Ștefănescu3,4, Smaranda Diaconescu5, Gheoghe G Bălan3,4, Nicoleta Gimiga6,7, Elena Rusu8, Cosmin Alec Moldovan5, Bogdan Popa7, Elena Tataranu9, Andrei Vasile Olteanu3,4, Alexandra Boloș1,2, Cristinel Ștefănescu1,2.
Abstract
Magnesium orotate has been cited in the medical literature for the past three years as a possible adjuvant in some pediatric and adult gastroenterological disorders associated with dysbiosis. Studies also focus on the possibility of adding magnesium orotate in psychiatric disorders' treatment, such as major depression and anxiety. The most relevant element in these studies is the efficiency of magnesium orotate therapy in cases with both gastroenterological and psychiatric symptoms. This article proposes a literature review, focused on the studies published in the last three years, targeting magnesium orotate treatment and probiotic supplementation in patients with both digestive and psychiatric symptoms. Moreover, this review will compare the efficiency of magnesium orotate and probiotics within both the pediatric and adult communities, focusing on the possibility of gut-brain axis modulation and its involvement in the clinical evolution of these patients.Entities:
Keywords: gastroenterology; magnesium; orotate; probiotics; psychiatry
Mesh:
Substances:
Year: 2022 PMID: 35458129 PMCID: PMC9029938 DOI: 10.3390/nu14081567
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Generic aspect of the bidirectional mechanism of the gut–brain axis (rebuild after Physio-Pedia: https://www.physio-pedia.com/File:Gut_Brain_Microbiome_Axis.png accessed on 26 March 2022).
Main bacterial genera involved in modulation of the gut–brain axis and possible candidates as combinative therapy alongside magnesium orotate.
| Genera | Neurochemical Involvement | Deficiency | Probiotic Therapeutical | Reference/ |
|---|---|---|---|---|
| Lactobacillus | GABA 1, BDNF 2, Vagal stimulation | FGID 3, behavior disorders, affective symptoms | Decrease intestinal distension, excitability and inflammation; decrease visceral pain by expression of opioid/cannabinoid receptors; mood and affective symptoms’ improvement | [ |
| Bifidobacterium | GABA, 5-HT 4 | Depression, anxiety, cognitive impairment, autism, ADHD 5, FGID | Behavioral symptom resolution, digestive symptoms clearing, neurodegenerative protection, visceral pain modulation | [ |
| Bacillus | 5-HT | Increased intestinal wall permeability, inflammation, oxidative stress, cognitive impairment, behavior and affective disorders | Decrease gastrointestinal inflammation, mood regulation | [ |
| Saccharomyces | Myeloperoxidase, acetylcholine esterase | Increases gut inflammation, oxidative stress, neuronal damage | Reduces inflammatory cytokine, neurodegenerative protection | [ |
| Enterococcus, Lactococcus | Dopamine, Histamine | Pathogenic bacteria overgrowth, gut inflammation, eating and affective disorders | Inhibits pathogenic bacteria overgrowth, reduces inflammation, histologic changes’ improvement, visceral pain reduction, mood and eating behavior improvement | [ |
| Streptococcus | 5-HT | Inflammatory response, depressive/anxiety symptoms, cognitive impairment, Autistic Spectrum Disorder (ASD 6) | Digestive symptoms relief, cognitive and affective improvement | [ |
| Bacteroides | Currently under study | Apparent role in neurodevelopment disorders (ADHD 5/ASD 6), functional digestive imbalances | Suggested cognitive/behavioral improvement, gastrointestinal function improvement in children with ASD/ADHD. | [ |
1 Gamma-aminobutyric acid; 2 Brain Derived Neurotrophyc Factor; 3 Functional gastrointestinal disorders; 4 5-hydroxytryptamine; 5 Attention-Deficit/Hyperactivity Disorder; 6 Autistic Spectrum Disorder.
Figure 2Molecular aspect of magnesium orotate (created with www.molview.org accessed on 27 March 2022).